C9orf72 ALS自然史与生物标志物前瞻性研究
该研究在美国和荷兰7家机构前瞻性收集116例症状性C9ALS和12例非ALS全扩增携带者的临床与人口学数据,并采集血、脑脊液和尸检样本。症状性队列平均起病年龄57.9±8.3岁,中位生存期36.9个月;血G4C2重复数与年龄正相关,脑脊液poly(GP)浓度与DNA扩增大小负相关但与疾病进展无关。
要点
- C9ALS症状性队列平均起病年龄57.9±8.3岁,中位生存期36.9个月。
- 血G4C2重复数与年龄正相关,脑脊液poly(GP)与DNA扩增大小负相关。
- 脑脊液poly(GP)浓度与疾病进展指标无关。
核心结论
- C9ALS临床特征较散发性ALS变异更小,研究为C9ALS临床试验设计提供基础。
- C9ALS患者病理与临床及人口学数据存在重要相关性。
研究设计与样本
- 前瞻性自然史研究,纳入7家机构的116例症状性C9ALS和12例非ALS全扩增携带者。
- 另通过病历回顾收集208例C9ALS和450例散发性ALS的回顾性临床数据。
主要发现
- 症状性前瞻队列平均起病年龄57.9±8.3岁,起病后中位生存期36.9个月。
- ALSFRS-R月变化为-1.8±1.7,慢肺活量月变化为预测值的-1.4%±3.24%。
- 血DNA中G4C2重复数与年龄正相关。
- 脑脊液poly(GP)浓度与DNA扩增大小负相关,但与疾病进展指标无关。
- 脑内poly(GP)二肽大小可达与DNA重复衍生物相似的较大尺寸。
临床怎么用
- C9ALS自然史数据可用于临床试验设计,如生存期和功能下降速率参考。
- 血G4C2重复数和脑脊液poly(GP)可作为C9ALS相关生物标志物进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To define the natural history of the C9orf72 amyotrophic lateral sclerosis (C9ALS) patient population, develop disease biomarkers, and characterize patient pathologies. METHODS: We prospectively collected clinical and demographic data from 116 symptomatic C9ALS and 12 non-amyotrophic lateral sclerosis (ALS) full expansion carriers across 7 institutions in the United States and the Netherlands. In addition, we collected blood samples for DNA repeat size assessment, CSF samples for biomarker identification, and autopsy samples for dipeptide repeat protein (DPR) size determination. Finally, we collected retrospective clinical data via chart review from 208 individuals with C9ALS and 450 individuals with singleton ALS. RESULTS: The mean age at onset in the symptomatic prospective cohort was 57.9 ± 8.3 years, and median duration of survival after onset was 36.9 months. The monthly change was -1.8 ± 1.7 for ALS Functional Rating Scale-Revised and -1.4% ± 3.24% of predicted for slow vital capacity. In blood DNA, we found that G4C2 repeat size correlates positively with age. In CSF, we observed that concentrations of poly(GP) negatively correlate with DNA expansion size but do not correlate with measures of disease progression. Finally, we found that size of poly(GP) dipeptides in the brain can reach large sizes similar to that of their DNA repeat derivatives. CONCLUSIONS: We present a thorough investigation of C9ALS natural history, providing the basis for C9ALS clinical trial design. We found that clinical features of this genetic subset are less variant than in singleton ALS. In addition, we identified important correlations of C9ALS patient pathologies with clinical and demographic data.
引用
- Cammack AJ, Atassi N, Hyman T, et al. Prospective natural history study of C9orf72 ALS clinical characteristics and biomarkers. Neurology. 2019. PMID: 31578300. doi:10.1212/WNL.0000000000008359
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。